↓ Skip to main content

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report

Overview of attention for article published in BMC Cancer, May 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
3 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report
Published in
BMC Cancer, May 2015
DOI 10.1186/s12885-015-1391-x
Pubmed ID
Authors

Dae Won Kim, Edelyn Barcena, Urvi N Mehta, Michelle L Rohlfs, Ashok J Kumar, Marta Penas-Prado, Kevin B Kim

Abstract

Leptomeningeal metastasis of melanoma is a devastating complication with a grave prognosis, and there are no known effective standard treatments. Although selective BRAF inhibitors have demonstrated a significant clinical activity in patients with metastatic melanoma harboring a BRAF mutation, the clinical benefit of BRAF inhibitor-based therapy in leptomeningeal disease is not clear. We present a case of prolonged survival of a patient with BRAF V600E-mutant leptomeningeal disease who was treated with vemurafenib followed by whole brain radiation and a combination of dabrafenib and trametinib. Both vemurafenib and the sequential treatment of radiation and dabrafenib/trametinib led to regression of the leptomeningeal disease, and the patient survived for 19 months after the diagnosis of the leptomeningeal disease. This case suggests a possible clinically meaningful benefit of BRAF inhibitor-based therapy and a need for close investigation of this therapeutic approach in patients with this devastating disease.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 21%
Student > Bachelor 3 11%
Student > Ph. D. Student 3 11%
Student > Master 3 11%
Student > Doctoral Student 1 4%
Other 1 4%
Unknown 11 39%
Readers by discipline Count As %
Medicine and Dentistry 10 36%
Biochemistry, Genetics and Molecular Biology 2 7%
Agricultural and Biological Sciences 2 7%
Nursing and Health Professions 1 4%
Unknown 13 46%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2015.
All research outputs
#2,032,636
of 5,114,519 outputs
Outputs from BMC Cancer
#657
of 2,830 outputs
Outputs of similar age
#64,725
of 162,355 outputs
Outputs of similar age from BMC Cancer
#52
of 188 outputs
Altmetric has tracked 5,114,519 research outputs across all sources so far. This one has received more attention than most of these and is in the 59th percentile.
So far Altmetric has tracked 2,830 research outputs from this source. They receive a mean Attention Score of 2.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 162,355 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 188 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.